Companies sponsors |
Gilead Sciences (idelalisib) |
Others |
Department of Health |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Leukaemia CARE |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
Accord Healthcare (fludarabine) (not participating, confidentiality agreement not signed) |
|
Actavis (fludarabine) (not participating, confidentiality agreement not signed) |
|
Allergan (fludarabine) (not participating, confidentiality agreement not signed) |
|
Aspen Pharma (chlorambucil) (not participating, confidentiality agreement not signed) |
|
Baxter Healthcare (cyclophosphamide) (not participating, confidentiality agreement not signed) |
|
Genzyme (fludarabine) (not participating, confidentiality agreement not signed) |
|
GlaxoSmithKline (chlorambucil,) (not participating, confidentiality agreement not signed) |
|
Hospira UK (fludarabine) (not participating, confidentiality agreement not signed) |
|
Janssen (ibrutinib) |
|
Pfizer (cyclophosphamide) |
|
Roche Products (rituximab) (not participating, confidentiality agreement not signed) |
|
Sandoz (cyclophosphamide) (not participating, confidentiality agreement not signed) |
|
Sanofi (fludarabine) (not participating, confidentiality agreement not signed) |
|
Teva UK (fludarabine) (not participating, confidentiality agreement not signed) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
|
National Institute for Health Research |